Vyvanse

Attention Deficit Hyperactivity Disorder, Binge-Eating Disorder

Treatment

20 Active Studies for Vyvanse

What is Vyvanse

Lisdexamfetamine

The Generic name of this drug

Treatment Summary

Lisdexamfetamine (also known as Vyvanse) is a medication used to treat attention deficit hyperactivity disorder (ADHD). It is made up of the essential amino acid L-lysine and the psychostimulant d-amphetamine. This drug works by increasing attention span, decreasing restlessness, and improving focus in people with ADHD. It is designed to be harder to abuse than other stimulants due to its delayed release after ingestion. After being taken orally, it is broken down into L-lysine and d-amphetamine by red blood cells, with the amount of d-amphetamine released into the bloodstream

Vyvanse

is the brand name

image of different drug pills on a surface

Vyvanse Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vyvanse

Lisdexamfetamine

2007

20

Effectiveness

How Vyvanse Affects Patients

Lisdexamfetamine dimesylate is a drug that is broken down into _d-amphetamine_ in the body. This stimulates the central nervous system and helps to increase alertness, focus, energy, and motivation. It works by releasing the neurotransmitters dopamine and norepinephrine from their storage sites in the brain.

How Vyvanse works in the body

Lisdexamfetamine is a drug that helps with ADHD. It works by increasing the amount of norepinephrine and dopamine in the brain. These are chemicals that help you to focus and pay attention. It does this by blocking a protein that would normally clear these chemicals out of the brain. This results in more of these chemicals staying in the brain, which can help you focus better. It also works on a receptor called the trace amine-associated receptor 1, but scientists are still learning about this pathway.

When to interrupt dosage

The measure of Vyvanse is contingent upon the diagnosed affliction. The amount of dosage will fluctuate as per the mode of delivery represented in the table beneath.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

20.0 mg, , 70.0 mg, 50.0 mg, 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg

Oral, , Capsule - Oral, Capsule, Tablet, chewable, Tablet, chewable - Oral

Binge-Eating Disorder

20.0 mg, , 70.0 mg, 50.0 mg, 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg

Oral, , Capsule - Oral, Capsule, Tablet, chewable, Tablet, chewable - Oral

Warnings

Vyvanse Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Open-angle glaucoma

Do Not Combine

advanced arteriosclerosis

Do Not Combine

Agitation

Do Not Combine

Hypertensive disease

Do Not Combine

Drug abuse

Do Not Combine

Hyperthyroidism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Lisdexamfetamine may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Lisdexamfetamine may interact with Pulse Frequency

There are 20 known major drug interactions with Vyvanse.

Common Vyvanse Drug Interactions

Drug Name

Risk Level

Description

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Lisdexamfetamine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Lisdexamfetamine.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Lisdexamfetamine.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Lisdexamfetamine.

Flecainide

Major

The metabolism of Flecainide can be decreased when combined with Lisdexamfetamine.

Vyvanse Toxicity & Overdose Risk

Taking too much amphetamine can cause restlessness, shaking, increased reflexes, rapid breathing, confusion, aggression, hallucinations, extreme body temperature, and muscle breakdown. It can also cause problems with the heart and blood vessels, including abnormal heart rhythms, high or low blood pressure, and shock. Other symptoms include nausea, vomiting, diarrhea, and stomach cramps. Taking very large doses can lead to death. Long-term use of amphetamine can damage nerve fibers in animals, but it is not known if this happens in humans. The toxic dose in rats is 7,060 mg/kg and in mice is 3,450 mg/

image of a doctor in a lab doing drug, clinical research

Vyvanse Novel Uses: Which Conditions Have a Clinical Trial Featuring Vyvanse?

81 active investigations are currently assessing the potential of Vyvanse to counteract Binge Eating Disorder (BED).

Condition

Clinical Trials

Trial Phases

Binge-Eating Disorder

2 Actively Recruiting

Phase 2, Not Applicable

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Vyvanse Reviews: What are patients saying about Vyvanse?

5

Patient Review

8/22/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

Our son is eight years old and he's been taking this medication for two years. It's really helped him become more calm, which has made a big difference in his life.

4.7

Patient Review

2/18/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

Vyvanse is the best ADHD medication that I have tried. It lasts a long time, works well, and has manageable side effects. You can't really judge an ADHD medicine within the first year of taking it, but I took Vyvanse for years! The only drawback is that it is very expensive and few insurances cover it.

4.3

Patient Review

4/30/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

I started this medication 3 months ago. It helped me to concentrate and function, but I developed some unpleasant side effects because of it. I now have Raynauds, and I experience joint pain and pins and needles in my skin since going to 40mg. Other than the side effects, it’s worth it to try! My 10 year old is also on it and has had no side effects.

3.3

Patient Review

4/27/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

I've been taking Vyvanse for a few weeks now and I definitely notice an improvement in my focus. However, the side effects are really harsh. I've felt dizzy, tired, nauseous, and even like I have arthritis! It's a tough decision to make whether the benefits are worth the drawbacks.

2.3

Patient Review

1/28/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

Vyvanse helped me focus at work, but I couldn't sleep while on it. Switching to Azstarys was a great decision because it lets me get the productivity benefits without sacrificing my rest.

2

Patient Review

11/4/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

For the first two weeks, this medication was great. However, I've since started experiencing anxiety, insomnia, and irritability. I would not recommend this to others.

1.3

Patient Review

8/11/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

I had a very negative experience when my doctor switched me from Adderall to Vyvanse. I was incredibly irritable and nasty while on this medication, and it made my skin crawl just hearing someone else speak. My mood would also change instantly, and I developed a rash shortly after taking it.

1

Patient Review

4/18/2022

Vyvanse for Binge Eating Disorder

Do not give this medication to your children. My 13 year old daughter was prescribed this and had terrible side effects including dizziness, headaches, pain in her legs, and insomnia. I regret giving her this medication.

1

Patient Review

4/28/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

Vyvanse didn't work for me at all. I found that it suppressed my appetite to the point where I couldn't get enough nutrients to support my workouts.

1

Patient Review

4/30/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

Over the course of five years, this drug ruined my life. It's not worth it.

1

Patient Review

10/20/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

Vyvanse was the doctor's first suggestion, but given my daughter's history of abusing medications, he instead recommended Azstarys. So far she's been doing great on it.

1

Patient Review

10/24/2022

Vyvanse for Attention Deficit Disorder with Hyperactivity

I took this for a few months for ADHD, it helped me concentrate, but it caused SEVERE depression with suicidal ideation and anxiety. It was scary, I thought I was going to lose my life. I stopped when I realized it was the Vyvanse, and the suicidal ideation ceased... but the depression took several months to come out of.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vyvanse

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Vyvanse make you do?

"Vyvanse increases the levels of norepinephrine and dopamine in your brain, which has the effect of stimulating your attention span."

Answered by AI

Is Vyvanse good for anxiety?

"If a child is having trouble with attention and is also anxious, the medication Vyvanse may help to reduce symptoms. However, Vyvanse is not a medication for anxiety specifically. In some cases, stimulant medications such as Vyvanse can actually increase anxiety in children who take them."

Answered by AI

How does Vyvanse make you feel?

"Amphetamines like Vyvanse can lead to a sense of euphoria or happiness. They can also help people feel more focused and alert. However, people may misuse these drugs to get more of these effects, which can lead to dependence and withdrawal symptoms."

Answered by AI

Clinical Trials for Vyvanse

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Vyvanse clinical trials?

We made a collection of clinical trials featuring Vyvanse, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Vyvanse clinical trials?

We made a collection of clinical trials featuring Vyvanse, we think they might fit your search criteria.
Go to Trials
Image of Hoskinson Health and Wellness Clinic in Gillette, United States.

Biofeedback and Lifestyle Interventions for ADHD

7 - 18
All Sexes
Gillette, WY

The Pediatric Healing Minds II intervention includes a biofeedback component, breathing practices nutrition and exercise counseling. Biofeedback is a type of mind-body technique used to control body functions such as heart, lung and muscle responses. Biofeedback uses therapeutic techniques that aim to help study participants gain more awareness and control over certain physiological functions in their bodies. It involves the use of electronic monitoring equipment to provide real-time information about physiological processes such as heart rate, HRV, coherence and muscle tension. This information is then provided back to the study participant, allowing them to learn how to consciously regulate these processes. During the sessions parents are expected to attend and participate. Study participants and parents will have access to a video that provides instructions for placement of the Heart Math single small ear lobe or finger sensor. Breathing Practices include alternate nostril, qi gong and other breathing practices. Nutrition counseling includes nutrition supplementation to correct deficiencies, dietary education and an age-and gender-specific diet prescription based on the Mediterranean Diet. Exercise counseling includes developmentally appropriate guidelines for cardiopulmonary, strength and flexibility activities based on guidelines from the American College of Sports Medicine (ACSM) and the American Academy of Pediatrics (AAP). The objective of this research proposal is to examine the combined effects of an integrative approach including biofeedback, breathing practices, nutrition and exercise counseling intervention (Healing Minds II), on symptoms and severity of ADHD, impulsivity and attention (e.g., QB continuous performance test) in youth 7-18 years of age. The investigators hypothesize that ADHD symptoms and severity, impulsivity and attention will be significantly improved and coherence increased after participation in the 6-month intervention. The investigators also propose that ADHD severity in those patients with prescribed medication but poorly-controlled ADHD will demonstrate the greatest improvement compared to those not prescribed medication and those who have well-controlled ADHD.

Waitlist Available
Has No Placebo

Hoskinson Health and Wellness Clinic

Inara McMaster, MD

Hoskinson Health and Wellness Clinic

Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Have you considered Vyvanse clinical trials?

We made a collection of clinical trials featuring Vyvanse, we think they might fit your search criteria.
Go to Trials